Caplin Point Laboratories - Public Comps and Valuation Multiples

Caplin Point Laboratories Overview

About Caplin Point Laboratories

Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.

Founded

1990

HQ

Employees

990

Website

caplinpoint.net

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $236M

LTM EBITDA $80.0M

EV

$1.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Caplin Point Laboratories Financials

As of September 2025, Caplin Point Laboratories reported last 12-month revenue of $236M and EBITDA of $80.0M.

In the same period, Caplin Point Laboratories achieved $67.1M in LTM net income.

See Caplin Point Laboratories valuation multiples based on analyst estimates

Caplin Point Laboratories P&L

In the most recent fiscal year, Caplin Point Laboratories reported revenue of $217M and EBITDA of $83.8M.

Caplin Point Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Caplin Point Laboratories valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$236M	XXX	$217M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$129M	XXX	XXX	XXX
Gross Margin	n/a	XXX	60%	XXX	XXX	XXX
EBITDA	$80.0M	XXX	$83.8M	XXX	XXX	XXX
EBITDA Margin	34%	XXX	39%	XXX	XXX	XXX
EBIT	$83.9M	XXX	$66.2M	XXX	XXX	XXX
EBIT Margin	36%	XXX	31%	XXX	XXX	XXX
Net Profit	$67.1M	XXX	$60.5M	XXX	XXX	XXX
Net Margin	28%	XXX	28%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Caplin Point Laboratories including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $236M. EBITDA for the last twelve months was $80.0M. In the most recent fiscal year, Caplin Point Laboratories achieved $217M in revenue and $83.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$236M	Analyst estimates available to subscribers	$217M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$129M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	59.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$80.0M	Analyst estimates available to subscribers	$83.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	33.9% EBITDA margin	Analyst estimates available to subscribers	38.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$83.9M	Analyst estimates available to subscribers	$66.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	35.6% EBIT margin	Analyst estimates available to subscribers	30.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$67.1M	Analyst estimates available to subscribers	$60.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	28.5% net profit margin	Analyst estimates available to subscribers	27.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Caplin Point Laboratories

This financial data table provides comprehensive performance metrics for Caplin Point Laboratories, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Caplin Point Laboratories generated $236M in revenue over the last twelve months.
The company achieved $80.0M in EBITDA over the last twelve months.
Net income over the last twelve months reached $67.1M.

Fiscal Year Performance

In the most recent fiscal year, Caplin Point Laboratories reported $217M in total revenue.
Fiscal year EBITDA was $83.8M.
The company maintained a gross profit margin of 59.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 38.7%.
Net profit margin reached 27.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Caplin Point Laboratories. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Caplin Point Laboratories Stock Performance

Caplin Point Laboratories has current market cap of INR 153B (or $1.7B), and EV of INR 144B (or $1.6B).

Market Cap Evolution

Caplin Point Laboratories Stock Data

As of October 17, 2025, Caplin Point Laboratories's stock price is INR 2017 (or $23).

See Caplin Point Laboratories trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.6B	$1.7B	XXX	XXX	XXX	XXX	$0.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Caplin Point Laboratories Valuation Multiples

Caplin Point Laboratories's trades at 7.8x EV/Revenue multiple, and 20.3x EV/EBITDA.

See valuation multiples for Caplin Point Laboratories and 15K+ public comps

Caplin Point Laboratories Financial Valuation Multiples

As of October 17, 2025, Caplin Point Laboratories has market cap of $1.7B and EV of $1.6B.

Equity research analysts estimate Caplin Point Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Caplin Point Laboratories has a P/E ratio of 25.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV (current)	$1.6B	XXX	$1.6B	XXX	XXX	XXX
EV/Revenue	6.9x	XXX	7.8x	XXX	XXX	XXX
EV/EBITDA	20.4x	XXX	20.3x	XXX	XXX	XXX
EV/EBIT	19.4x	XXX	25.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	25.8x	XXX	29.7x	XXX	XXX	XXX
EV/FCF	45.7x	XXX	64.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Caplin Point Laboratories Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Caplin Point Laboratories Margins & Growth Rates

Caplin Point Laboratories's last 12 month revenue growth is 18%

Caplin Point Laboratories's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Caplin Point Laboratories's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Caplin Point Laboratories's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Caplin Point Laboratories and other 15K+ public comps

Caplin Point Laboratories Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	18%	XXX	17%	XXX	XXX	XXX
EBITDA Margin	34%	XXX	38%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	11%	XXX	XXX	XXX
Rule of 40	56%	XXX	56%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	79%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	29%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial